Clinical Trials · NCT00690235

Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia

CompletedPhase 4Pramlintide (Approved)
Phase
Phase 4
Recruitment status
Completed
Sponsor
University of Texas Southwestern Medical Center
Enrollment
33
Start date
Nov 2007
Locations
1 site, United States
Primary endpoint
Weight Loss With Pramlintide in Persons With Schizophrenia Who Have Gained Weight Taking Olanzapine or Clozapine
View Pramlintide compound reference